Drug Trial Radar · NCT06324604
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jun 13, 2024
Primary completion
Mar 31, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Mozart Therapeutics Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.
Conditions
- Healthy Volunteers
- Type 1 Diabetes
Interventions
PlaceboDrug
MTX-101
MTX-101Drug
MTX-101 (bispecific CD8 Treg modulator)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of single, ascending dose levels of MTX-101Time frame: Enrollment to 8 weeks post dose
- Safety of multiple, ascending dose levels of MTX-101Time frame: Enrollment to 11 weeks following the last dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
St Vincent's Hospital Melbourne (SVHM)
Fitzroy, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
The Royal Melbourne Hospital
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.